Edition:
United States

Miragen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

7.37USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,510
52-wk High
$17.83
52-wk Low
$4.65

Latest Key Developments (Source: Significant Developments)

Miragen says MRG-106 continued to be generally well-tolerated at all dose levels
Monday, 11 Dec 2017 04:05pm EST 

Dec 11 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS INC - ANNOUNCED NEW INTERIM RESULTS FROM PHASE 1 CLINICAL TRIAL OF MRG-106 IN PATIENTS WITH MYCOSIS FUNGOIDES (MF) FORM OF CTCL.MIRAGEN THERAPEUTICS INC - MRG-106 CONTINUED TO BE GENERALLY WELL-TOLERATED AT ALL DOSE LEVELS EVALUATED AS OF DECEMBER 4, 2017.MIRAGEN THERAPEUTICS INC - INITIATED DOSING IN THREE ADDITIONAL ONCOLOGY INDICATIONS.MIRAGEN THERAPEUTICS INC - PLAN TO INITIATE A CONTROLLED PHASE 2 TRIAL IN H2 2018 TO FURTHER EVALUATE POTENTIAL OF MRG-106.  Full Article

Miragen Therapeutics reports third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 revenue $1.6 million versus $900,000.Q3 revenue view $306,000 -- Thomson Reuters I/B/E/S.Miragen Therapeutics Inc - ‍cash and cash equivalents at september 30, 2017 were $42.8 million, compared to $22.1 million at December 31, 2016​.Miragen Therapeutics Inc - qtrly ‍net loss per share, basic and diluted $0.27​.  Full Article

Signal Genetics receives extension to comply with Nasdaq continued listing requirement
Thursday, 26 May 2016 08:30am EDT 

Signal Genetics Inc : Signal Genetics receives extension to comply with Nasdaq continued listing requirement .Received notification from Nasdaq that it has an additional 180-day period, or until November 21, 2016, to regain compliance.  Full Article

Signal Genetics Q1 loss per share $0.26
Monday, 16 May 2016 08:45am EDT 

Signal Genetics Inc : Qtrly loss per share $0.26 . Q1 earnings per share view $-0.28, revenue view $750,000.00 -- Thomson Reuters I/B/E/S . Signal genetics highlights recent achievements and reports first quarter 2016 financial results .Q1 revenue $818,000 versus $645,000.  Full Article

BRIEF-Miragen Therapeutics reports third quarter financial results

* Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update